Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2016-08-25

Original market date: See footnote 1

2009-03-20

Product name:

BLEOMYCIN FOR INJECTION

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section .

DIN:

02265982

Product Monograph/Veterinary Labelling:

Date: 2016-06-01 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company: 

FRESENIUS KABI CANADA LTD
165 Galaxy Blvd, Suite 100
Toronto
Ontario
Canada  M9W 0C8

Class: 

Human

Dosage form(s):

Powder For Solution

Route(s) of administration:

Subcutaneous,  Intrapleural,  Intravenous,  Intramuscular

Number of active ingredient(s):

1

Schedule(s):

Prescription  

Biosimilar Biologic Drug:

No

American Hospital Formulary Service (AHFS): See footnote 3

10:00.00   ANTINEOPLASTIC AGENTS

Anatomical Therapeutic Chemical (ATC): See footnote 4

L01DC01  BLEOMYCIN

Active ingredient group (AIG) number:See footnote 5

0133328001

List of active ingredient(s)
Active ingredient(s) Strength
BLEOMYCIN (BLEOMYCIN SULFATE) 15 UNIT / VIAL

Application information

Related information

Contact us

Version 3.8.0
Date modified: